Biology and Management of Multiple Myeloma

  • James R. Berenson

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Robert A. Kyle, Daniel E. Bergsagel
    Pages 1-11
  3. Robert A. Vescio, James R. Berenson
    Pages 37-53
  4. Johannes Drach, Sonja Seidl, Jutta Ackermann, Hannes Kaufmann
    Pages 55-67
  5. John De Vos, Bernard Klein
    Pages 69-91
  6. Douglas E. Joshua
    Pages 127-136
  7. Meletios A. Dimopoulos, Robert A. Kyle
    Pages 137-157
  8. Jean-Luc Harousseau, Michel Attal, Gary J. Schiller
    Pages 159-182
  9. Gösta Gahrton, Kenneth C. Anderson, William Bensinger
    Pages 183-203
  10. Hakan Mellstedt, Maurizio Bendandi, Anders Österborg, Larry W. Kwak
    Pages 205-221
  11. Heinz Ludwig, Niklas Zojer
    Pages 223-249
  12. James R. Berenson
    Pages 251-279
  13. Alan Solomon, Deborah T. Weiss, Guillermo A. Herrera
    Pages 281-302
  14. Heinz Ludwig, Anders Österborg
    Pages 303-318
  15. Terry H. Landowski, William S. Dalton, Sydney E. Salmon
    Pages 319-353
  16. Back Matter
    Pages 355-366

About this book


Bone marrow-based malignancy is becoming more commonplace. There have also been major advances in the diagnosis, pathogenesis, and treatment of this common tumor type. In Biology and Management of Multiple Myeloma, expert physicians and clinical researchers summarize and explain the recent advances in the biology and treatment of this common B-cell tumor. On the biological side, the authors review the many important, clinically relevant discoveries that have been made in the last few years. They show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents. The role of high-dose therapy is also discussed, along with the treatment of such complications as renal disease, anemia, and bone disease.
Comprehensive and authoritative, Biology and Management of Multiple Myeloma offers both clinicians and researchers a thoroughly up-to-date understanding of the new biology that can be directly applied not only to future laboratory studies, but also to the optimal treatment of myeloma patients today.


Staging anemia bone marrow cell cytokines pathogenesis plasma stem cell stem cell transplantation transplantation tumor

Editors and affiliations

  • James R. Berenson
    • 1
  1. 1.Institute for Myeloma and Bone Cancer ResearchLos AngelesUSA

Bibliographic information